Literature DB >> 18974153

Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.

Veronica Yao1, Anil Parwani, Christoph Maier, Warren DeWayne Heston, Dean John Bacich.   

Abstract

Increased expression of PSMA, a differentiation antigen with folate hydrolase activity, is an independent marker of prostate cancer progression. Mice expressing moderate levels of human PSMA in their prostate develop PIN-like lesions by 9 months. The aim of this study was to determine whether PSMA is involved in prostate carcinogenesis and progression and, if so, the possible mechanism by which PSMA may exert its effects. Using prostates from PSMA-transgenic mice, we developed a tissue recombinant model that exhibits small atypical glands with features of adenocarcinoma. This was not observed in tissue recombinants that were composed of prostate tissues from the wild-type siblings. Cells from PSMA-transgenic tissue recombinants have the ability to form colonies in semisolid agar. PSMA may facilitate this phenotype by increasing the invasive ability of cells. Ectopic PSMA expression on PC-3 cells increased the invasive capacity of cells in in vitro invasion assays, which could be competed out by folic acid. These results suggest PSMA facilitates the development of prostate cancer, and the invasive ability of these cells may be modulated by folate levels. These findings show a novel mechanism that may contribute to the known role of folate in cancer prevention, and may lead to the use of PSMA inhibitors as novel chemopreventive agents for prostate cancer. Moreover, our model should prove useful for further dissecting pathways involved in prostate carcinogenesis and progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974153      PMCID: PMC2748916          DOI: 10.1158/0008-5472.CAN-08-2328

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells.

Authors:  R G Lapidus; C W Tiffany; J T Isaacs; B S Slusher
Journal:  Prostate       Date:  2000-12-01       Impact factor: 4.104

2.  Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium.

Authors:  V H Freedman; S I Shin
Journal:  Cell       Date:  1974-12       Impact factor: 41.582

3.  An ultrastructural study of hormonally induced squamous metaplasia in the coagulating gland of the mouse prostate.

Authors:  T J Triche; J C Harkin
Journal:  Lab Invest       Date:  1971-12       Impact factor: 5.662

4.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.

Authors:  Minjung J Kim; Rajula Bhatia-Gaur; Whitney A Banach-Petrosky; Nishita Desai; Yuzhuo Wang; Simon W Hayward; Gerald R Cunha; Robert D Cardiff; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

5.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors:  S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

6.  Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells.

Authors:  N H Colburn; W F Bruegge; J R Bates; R H Gray; J D Rossen; W H Kelsey; T Shimada
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

7.  A human prostatic epithelial model of hormonal carcinogenesis.

Authors:  Y Wang; D Sudilovsky; B Zhang; P C Haughney; M A Rosen; D S Wu; T J Cunha; R Dahiya; G R Cunha; S W Hayward
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

9.  Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.

Authors:  Denise S O'Keefe; Dean J Bacich; Warren D W Heston
Journal:  Prostate       Date:  2004-02-01       Impact factor: 4.104

10.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  31 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Opposing roles of folate in prostate cancer.

Authors:  Kevin J Rycyna; Dean J Bacich; Denise S O'Keefe
Journal:  Urology       Date:  2013-08-28       Impact factor: 2.649

Review 3.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

Review 4.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 5.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Deficiency of DNA repair nuclease ERCC1-XPF promotes prostate cancer progression in a tissue recombination model.

Authors:  Derek J Matoka; Veronica Yao; Diana S Harya; Jennifer L Gregg; Andria R Robinson; Laura J Niedernhofer; Anil V Parwani; Christoph Maier; Dean J Bacich
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

7.  PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Esther Mena; Amanda L Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario Eisenberger; Michael Carducci; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Zsolt Szabo; Martin G Pomper; Steve Y Cho
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 8.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

9.  Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Anthony Ciarallo; Esther Mena; Amanda Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci; Ashley E Ross; Philip W Kantoff; Daniel P Holt; Robert F Dannals; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-10-22       Impact factor: 10.057

10.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.